Last updated on September 2018

Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases


Brief description of study

Stereotactic radiosurgery (SRS) is increasingly administered as the sole treatment of brain metastases, in order to spare acute and long term side effects associated with whole brain radiotherapy. Local control of SRS treated lesions is good, but patients tend to develop additional brain metastases subsequently.

Nivolumab is a modulator of the immune system. Treatment with Nivolumab is associated with an increase in local control and survival in patients with non-small cell lung cancer and clear cell renal cell carcinoma. In the presence of Nivolumab, treatment of brain metastases with SRS may trigger an immune reaction against cancer. Therefore, the combination of SRS with Nivolumab may reduce the development of new brain metastases and improve patient survival.

The purpose of this study is to assess the effect of combining Nivolumab and SRS in controlling cancer progression. SRS will be administered to patients while they are receiving Nivolumab.

Clinical Study Identifier: NCT02978404

Contact Investigators or Research Sites near you

Start Over

Philip Wong, MD, FRCPC

Centre Hospitalier de l'Universit de Montr al
Montreal, QC Canada
  Connect »

Valerie Panet-Raymond, MD

McGill University Health Centre
Montreal, QC Canada
  Connect »

Marc-Emile Plourde, MD

Centre Hospitalier Universitaire de Sherbrooke
Sherbrooke, QC Canada
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.